How Much Does Ozempic, Wegovy, or Mounjaro Really Cost?
Calculate the real cost of GLP-1 medications with and without insurance. Compare brand-name, compounded, and generic options.
GLP-1 Medication Costs in 2026
GLP-1 receptor agonists — including Ozempic, Wegovy, Mounjaro, and Zepbound — are among the most prescribed medications in America. They are also among the most expensive. Without insurance, brand-name GLP-1 medications cost $900-1,350 per month ($10,800-16,200 per year). With insurance coverage, copays range from $25-50/month. The gap between cash and insured prices is one of the largest in pharmaceutical history.
Brand-Name vs. Compounded: What Are the Options?
Brand-name (Ozempic, Wegovy, Mounjaro, Zepbound): FDA-approved, manufactured by Novo Nordisk or Eli Lilly. Highest cost but most studied and standardized. Available through regular pharmacies with a prescription.
Compounded semaglutide/tirzepatide: Prepared by compounding pharmacies at $150-300/month. These are custom-made versions of the same active ingredient, available when the brand-name is in shortage or at a physician's discretion. Quality and availability vary by pharmacy. The FDA allows compounding during drug shortages but has taken action against some compounders as shortages resolve.
Insurance Coverage Landscape
Coverage varies dramatically by insurer and indication. Most insurance plans cover Ozempic and Mounjaro for Type 2 diabetes with reasonable copays ($25-75/month). Coverage for weight loss (Wegovy, Zepbound) is more limited — many plans exclude weight loss medications or require prior authorization with documented BMI, failed diet attempts, and comorbidities.
Medicare Part D began covering GLP-1s for weight loss in 2026 for patients with BMI ≥ 30 (or ≥ 27 with comorbidities), expanding access to millions of seniors. Employer-sponsored plans are increasingly adding coverage due to evidence that GLP-1s reduce healthcare costs from obesity-related conditions.
Is It Worth the Cost? The Health Economics
Clinical trials show 15-22% body weight loss over 68 weeks with semaglutide (Wegovy) and 20-26% with tirzepatide (Zepbound). Beyond weight loss, GLP-1s show cardiovascular benefits, reduced inflammation, and improved metabolic markers. The question is whether $10,000-16,000/year is justified by health outcomes.
Studies suggest that for patients with obesity-related conditions (Type 2 diabetes, hypertension, sleep apnea), GLP-1s can reduce overall healthcare spending by avoiding hospitalizations, surgeries, and long-term disease management. For cosmetic weight loss without comorbidities, the cost-benefit calculation is more personal.
The price gap between brand-name and compounded semaglutide is roughly 5-7x ($1,350/month vs $200/month). As brand-name shortages resolve, the FDA may restrict compounded versions, potentially eliminating the lower-cost option for many patients.
